LH

LH

USD

Labcorp Holdings Inc. Common Stock

$247.660+3.180 (1.301%)

Reaalajas hind

Healthcare
Diagnostics & Research
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$244.480

Kõrge

$248.720

Madal

$243.325

Maht

0.22M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

20.7B

Tööstusharu

Diagnostics & Research

Riik

United States

Kauplemisstatistika

Keskmine maht

0.78M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $191.97Praegune $247.660Kõrge $258.59

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 30. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

LH (Labcorp Holdings Inc. Common Stock): Analyzing Recent Moves & What Might Come Next

Stock Symbol: LH Generate Date: 2025-04-30 23:16:33

Alright, let's break down what's been happening with Labcorp (LH) based on the latest info we've got. Think of this as a quick check-in on the stock's pulse.

Recent News Buzz: What's the Vibe?

Looking at the news headlines from April, it feels a bit like a mixed bag, but with some recent positive nudges. We saw a couple of analysts, Barclays and Baird, actually raise their price targets for Labcorp just in the last day or two. Baird's target went up to $267, and Barclays bumped theirs to $250. That's generally seen as a good sign – analysts think the stock could be worth more than they previously did.

Now, it wasn't all straight up. Earlier in April, Truist lowered their target slightly to $274, and Barclays had also lowered theirs before the recent increase. So, there's been some back and forth among the pros.

On the company front, Labcorp announced their first-quarter results recently (April 29th), which is a big event investors watch closely. They also declared a quarterly dividend back on April 10th. Earnings reports and dividends are usually positive signals, showing the company is operating and returning value to shareholders.

Putting it together, the news sentiment seems cautiously optimistic right now, especially with those recent price target increases coming right after the Q1 results announcement. The overall feeling leans positive, driven by analyst confidence bumps and standard corporate actions like earnings and dividends.

Price Action: What's the Stock Been Doing?

Checking out the price chart over the last couple of months tells an interesting story. Labcorp's stock price had a tough stretch through March and into early April. It dropped quite a bit from highs in the $250s down towards the $210-$220 range. It was a pretty clear downtrend for a while there.

But then, something shifted. In the last few days of April, particularly on the 29th, the stock saw a significant jump. It bounced back strongly, and the trading volume that day was much higher than average – over 2.2 million shares traded, compared to a typical day around 770,000. High volume on a price move often suggests conviction behind that move. The price continued to hold up on April 30th, closing around $241.

So, after a noticeable dip, the stock has shown a strong recent recovery. The current price is right in the middle of this recent bounce-back action.

Outlook & Ideas: Putting It All Together

Based on the recent news, the price bounce, and what the AI model is predicting, the near-term picture for LH seems to be leaning positive.

Here's why:

  1. The Bounce is Real: The stock price has clearly reversed its recent slide and made a strong move up in the last couple of days of April, backed by solid volume.
  2. Analysts Are Reacting: Those recent price target increases from Barclays and Baird suggest analysts are seeing something positive, perhaps related to the Q1 results or future prospects.
  3. AI is Bullish: The AI prediction model is forecasting continued upward movement for the next few days, with predicted increases of over 2% each day. It even has a high confidence score and tags like "News-Driven Surge" and "AI-Enhanced Insight," suggesting the recent news and its own analysis point upwards. The AI's projected target price is around $259.31.

Given this setup, the current situation might suggest a potential 'buy' or 'accumulate' window for those interested in LH.

Potential Entry Consideration: If you were considering getting in, the current price area, around $240-$241, could be a point to watch. It's where the stock closed after its recent strong move and aligns with the AI's immediate prediction for today. The AI's recommended entry points are also right around this level ($240.07, $241.74).

Potential Exit/Stop-Loss Consideration: Managing risk is key. A potential stop-loss level could be placed below the recent lows seen in early-to-mid April, or perhaps around the AI's suggested stop-loss of $216.38. This level is well below the recent bounce and would signal that the upward momentum has failed. For taking profits, the AI's projected target of $259.31 or its suggested take-profit level of $255.2 could be areas to consider, aligning with some of the higher analyst price targets as well.

Company Context: What Labcorp Does

Remember, Labcorp is a major player in the Healthcare sector, specifically in Diagnostics & Research. They run labs and provide a huge range of testing services. This means their business is tied to healthcare trends, doctor visits, and potentially drug development (through their Biopharma segment). News like earnings reports are particularly important because they show how the core business is performing. The recent Q1 results announcement is likely a key factor influencing both the price action and the analyst/AI outlooks.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

Analyst Upgrades

Barclays Maintains Equal-Weight on Labcorp Hldgs, Raises Price Target to $250

Barclays analyst Jack Meehan maintains Labcorp Hldgs with a Equal-Weight and raises the price target from $240 to $250.

Vaata rohkem
Barclays Maintains Equal-Weight on Labcorp Hldgs, Raises Price Target to $250
Analyst Upgrades

Baird Maintains Outperform on Labcorp Hldgs, Raises Price Target to $267

Baird analyst Eric Coldwell maintains Labcorp Hldgs with a Outperform and raises the price target from $253 to $267.

Vaata rohkem
Baird Maintains Outperform on Labcorp Hldgs, Raises Price Target to $267
PR Newswire

Labcorp Announces 2025 First Quarter Results

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March...

Vaata rohkem
Labcorp Announces 2025 First Quarter Results
Analyst Upgrades

Truist Securities Maintains Buy on Labcorp Hldgs, Lowers Price Target to $274

Truist Securities analyst David Macdonald maintains Labcorp Hldgs with a Buy and lowers the price target from $285 to $274.

Vaata rohkem
Truist Securities Maintains Buy on Labcorp Hldgs, Lowers Price Target to $274
Analyst Upgrades

Barclays Maintains Equal-Weight on Labcorp Hldgs, Lowers Price Target to $240

Barclays analyst Jack Meehan maintains Labcorp Hldgs with a Equal-Weight and lowers the price target from $260 to $240.

Vaata rohkem
Barclays Maintains Equal-Weight on Labcorp Hldgs, Lowers Price Target to $240
PR Newswire

Labcorp Declares Quarterly Dividend

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors...

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 3. mai 2025, 08:12

LangevNeutraalneTõusev

70.3% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Konservatiivne
Kauplemisjuhend

Sisenemispunkt

$248.34

Võta kasum

$252.62

Peata kahjum

$222.90

Põhitegurid

PDI 6.1 on MDI 5.6 kohal ADX-iga 20.0, mis viitab tõusutrendile
Praegune hind on tugitasemele ($247.47) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 14.8x keskmisest (9,024), mis viitab äärmiselt tugevale ostusurvele
MACD 0.3164 on signaalijoone 0.3417 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.